New criteria for diagnosing vascular dementia

Embargoed until: Publicly released: 2025-09-16 17:50

Australia; NSW; VIC

Photo by Robina Weermeijer on Unsplash

Vascular dementia is the second most common form of dementia, accounting for 15% to 20% of cases, and now an Australian-led consortium has released updated criteria for diagnosing the condition, the first update in over ten years. The new criteria provide additional guidance on potential neuroimaging and fluid biomarkers. The authors say the new criteria should provide an international standard for diagnosing the condition.

Media release

From:

Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia—The VasCog-2-WSO Criteria
JAMA Neurology

About The Study:
The International Society for Vascular Behavioural and Cognitive Disorders (VasCog)-2- WorldStroke Organization (WSO) criteria update the VasCog criteria for the diagnosis of vascular cognitive impairment and dementia (VCID), providing operationalization and additional guidance on potential neuroimaging and fluid biomarkers. VasCog-2-WSO should provide an international standard for VCID diagnosis, facilitating diagnostic consistency among clinicians and researchers.

(doi:10.1001/jamaneurol.2025.3242)

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JAMA Neurology

Research:Paper

Organisation/s: The University of New South Wales, Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney, Monash University, Garvan Institute of Medical Research

Funder: This work was supported in part by The Centre for Healthy Brain Ageing (CHeBA), University of New SouthWales, supported by the NHMRC Centres of Research Excellence (CRE) scheme (RG203943; 2021-2026) (Drs Sachdev, Bentvelzen, Jiang, Hosoki, Chander, Saks); grants from Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie (Dr Aben); National Institutes of Health (Drs Briceno, Gorelick, Pase); National Heart Foundation of Australia (Dr Brodtmann); senior researcher scholarship (bolsa de produtividade em pesquisa) from CNPq, Brazil (Dr Caramelli); the National Medical Research Council of Singapore (Dr Chen); Peter Duncan Neuroscience Unit at St Vincent’s Applied Medical Research Centre (Dr Cysique); MRC grant MR/ T001402/1 (Dr Geranmayeh); the French Department of Health Direction Générale de l’Offre Des Soins grant DGOS R1/2013/144 (Dr Godefroy); NIHR Cambridge Biomedical Research Centre and the Medical Research Council funded Dementias Platform UK (Dr O’Brien); support from the Australian National Health and Medical Research Council Investigator grant (GTN2009264), Brain Foundation and Alzheimer’s Association (Dr Pase); Australian National Health and Medical Research Council Investigator grant GTN2009264 (Dr Pase); NIA South Texas Alzheimer’s Disease Center Genetics and Multiomics Core grant P30 AG066546 (Dr Seshadri); NIHR Oxford Biomedical Research Centre (Dr Pendlebury); research fellowship grant from Alzheimer’s Association and University of Geneva (Dr Sveikata); UK Dementia Research Institute funded by the Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK (DrWardlaw).

Media Contact/s

Contact details are only visible to registered journalists.